Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The role and modulation of the inflammasome in the sickle cell disease oral phenotype in female mice

Kai Clarke, Marja Hurley, Liping Xiao Nov 03, 2025 pp. 6484-6484 10.1182/blood-2025-6484

Abstract Sickle Cell Disease (SCD) is the most common inherited blood disorder affecting millions worldwide. SCD is caused by a genetic muta...

Outcomes of immune thrombocytopenia hospitalizations in patients with diabetes mellitus

Amro Awad, Margaret Crosby, Maria Diaz et al. Nov 03, 2025 pp. 1261-1261 10.1182/blood-2025-1261

Abstract Background: Corticosteroid therapy is the first-line treatment of immune thrombocytopenia (ITP) with moderate to severe thrombocyto...

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Murali Janakiram, Thomas Martin, Mrugakshi Dave et al. Nov 03, 2025 pp. 4598-4598 10.1182/blood-2025-4598

Abstract Background: BCMA- and GPRC5D-targeting immunotherapies including CART cell therapy and Bispecific antibodies ar...

Increased serum h-ferritin and its imbalance with l-ferritin distinguish hemophagocytic lymphohistiocytosis among critically ill patients with hyperferritinemia.

France Debaugnies, Fleur Wolff, Francis Impens et al. Nov 03, 2025 pp. 4764-4764 10.1182/blood-2025-4764

Abstract Serum Ferritin is a sensitive screening parameter to diagnose hemophagocytic lymphohistiocytosis (HLH) in critically ill patients b...

Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models

Mawar Karsa, Patrick Connerty, Ayu Karsa et al. Nov 03, 2025 pp. 3282-3282 10.1182/blood-2025-3282

Abstract Introduction While the survival rate of paediatric acute lymphoblastic leukaemia (ALL) has increased up to 90%, the prognosis for bo...

Long-term outcomes of dexamethasone prophylaxis after axicabtagene ciloleucel for non-Hodgkin lymphoma: A single-center retrospective study

Christina Darwish, Rashmi Khanal, Helen Gandler et al. Nov 03, 2025 pp. 4539-4539 10.1182/blood-2025-4539

Abstract Background: A small cohort of patients receiving prophylactic dexamethasone (dex) after axicabtagene ciloleucel (axi-cel) within ZU...

Identifying educational and resource needs of general internal medicine physicians in sickle cell disease management.

Anas Samman, Victoria David, Roy Khalifé et al. Nov 03, 2025 pp. 8206-8206 10.1182/blood-2025-8206

Abstract Background: Sickle cell disease (SCD) presents with a wide spectrum of acute and chronic complications that require timely recognit...

Prognostic factors influencing relapse and survival of childhood acute lymphoblastic leukemia with the ALL-BFM IC 2009 protocol

Baran Alkan, dorukcan alkan, Gizem Cilsaat et al. Nov 03, 2025 pp. 6836-6836 10.1182/blood-2025-6836

Abstract Background: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, remaining the fourth leading cause of dea...

Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism

Nithin Thomas, Raphiel Murden, Stacey Fedewa et al. Nov 03, 2025 pp. 3128-3128 10.1182/blood-2025-3128

Abstract Introduction: Balancing the safety and efficacy of anticoagulation (AC) for venous thromboembolism (VTE) among patients with thromb...

Revisiting acute chest syndrome (ACS) associated with sickle cell disease (SCD) vaso-occlusive pain episodes (VOE): Insight from a prospective, multicenter Phase-3 randomized controlled trial

Dunia Hatabah, Fahd Ahmad, Gladstone Airewele et al. Nov 03, 2025 pp. 2946-2946 10.1182/blood-2025-2946

Abstract Background: ACS occurs in up to 20% of hospitalized patients with SCD-VOE, often prolonging and complicating hospital stay. Despite...

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Haiqiong Zheng, Houli Zhao, Xin Jin et al. Nov 03, 2025 pp. 5900-5900 10.1182/blood-2025-5900

Abstract Background Recently, CD7-targeted CAR-T cells have shown both safety and efficacy in early-stage clinical studi...

Role in of primary VTE prophylaxis in pediatric patients in hospitalized and critically ill settings: A systematic review and meta-analysis

Ali Choaib, Muayad Azzam, Jana Khawandi et al. Nov 03, 2025 pp. 3137-3137 10.1182/blood-2025-3137

Abstract Venous thromboembolism (VTE) is a major cause of morbidity in hospitalized and critically ill children . Currently there is a lack o...

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Hannah Goulart, Caitlin Rausch, Elias Jabbour et al. Nov 03, 2025 pp. 5204-5204 10.1182/blood-2025-5204

Abstract Background Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression in proliferating cells and are commonly dys...

ATM dysfunction across ataxia telangiectasia and leukemias: A systematic review of genetic drivers and functional impact

Gokulakrishnan Sankaran, Gurunathan Srinivasan, Haran Srinivasan Saravanan et al. Nov 03, 2025 pp. 6779-6779 10.1182/blood-2025-6779

Abstract Introduction Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder caused by mutations in the ATM gene. Both germline a...

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Gabriel Brisou, Roch Houot, Roberta Di Blasi et al. Nov 03, 2025 pp. 4541-4541 10.1182/blood-2025-4541

Abstract Introduction: Lisocabtagene maraleucel (liso-cel) has demonstrated superior effectiveness as second-line (2L) t...

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

Yoshinobu Konishi, Giuseppe Tarantino, Yiwen He et al. Nov 03, 2025 pp. 5702-5702 10.1182/blood-2025-5702

Abstract Introduction While spatial analysis has identified immune features predicting immunotherapy response in solid tumors, spatial infor...

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes

Muharrem Muftuoglu, Sandeep Singh, Andrea Bedoy et al. Nov 03, 2025 pp. 263-263 10.1182/blood-2025-263

Abstract Background: Immunotherapy has transformed cancer care, inducing durable responses in both hematologic and solid tumors. Despite the...

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Uma Borate, Shivani Handa, Kaitlyn Dvorak-Kornaus et al. Nov 03, 2025 pp. 238-238 10.1182/blood-2025-238

Abstract Introduction: Therapy related-MDS (tMDS), a known sequalae of genotoxic therapies, is a highly aggressive form of MDS accounting fo...

Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial

Hai-Xia Fu, Yuanyuan Zhang, Xiao-Dong Mo et al. Nov 03, 2025 pp. 377-377 10.1182/blood-2025-377

Abstract Introduction: Delayed platelet (PLT) recovery is a common complication following haploidentical hematopoietic s...

A review and analysis of reported global blood and marrow transplantation costs in comparison to macroeconomic factors including gross national income per capita and out-of-pocket health expenditures

Syed Shahrukh Rizvi, Amaara Babwah, Damiano Rondelli Nov 03, 2025 pp. 4427-4427 10.1182/blood-2025-4427

Abstract Introduction: Despite increasing blood and marrow transplantation activity globally throughout the last few decades, regional and e...

High fructose diet exacerbates acute GVHD through microbiota dysbiosis and HIF-1α–mediated macrophage activation

Kunpeng Wu, Huihui Yu, Kankan Cao et al. Nov 03, 2025 pp. 4082-4082 10.1182/blood-2025-4082

Abstract Background Acute graft-versus-host disease (aGVHD) is a life-threatening complication following allogeneic hematopoietic stem cell t...

Splenic dysfunction in young children with sickle cell disease

Gaby Stegemann, Celine Rook, Hanke Matlung et al. Nov 03, 2025 pp. 1179-1179 10.1182/blood-2025-1179

Abstract Introduction: Sickle cell disease (SCD) is a hemoglobinopathy characterized by sickle cell shaped deformation of red blood cells le...

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Sigrun Einarsdottir, Maria Isabel Sotelo, Teng Fei et al. Nov 03, 2025 pp. 4498-4498 10.1182/blood-2025-4498

Abstract Background: Infectious complications are the leading cause of non-relapse mortality following CAR-T cell therapy. Respiratory viral...

Psychiatric comorbidities and the mortality paradox in sickle cell disease: A national inpatient analysis

Canan Dirican, Anas Al Mardini, Bolivia Fernandes et al. Nov 03, 2025 pp. 4447-4447 10.1182/blood-2025-4447

Abstract Background: Sickle cell disease (SCD) is a genetic hemoglobinopathy which causes recurrent hospitalization. Psychiatric comorbiditi...

MYC partners with kinase-independent PIM2 at key promoters in multiple myeloma

Christopher Schorr, Alexander Kinstedt, Daniela Petrusca et al. Nov 03, 2025 pp. 7466-7466 10.1182/blood-2025-7466

Abstract Introduction: Multiple Myeloma (MM) is an incurable hematological malignancy characterized by abnormal plasma cell proliferation in...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page